[go: up one dir, main page]

PE20030617A1 - Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen - Google Patents

Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen

Info

Publication number
PE20030617A1
PE20030617A1 PE2001000970A PE2001000970A PE20030617A1 PE 20030617 A1 PE20030617 A1 PE 20030617A1 PE 2001000970 A PE2001000970 A PE 2001000970A PE 2001000970 A PE2001000970 A PE 2001000970A PE 20030617 A1 PE20030617 A1 PE 20030617A1
Authority
PE
Peru
Prior art keywords
amino
acid
methyl
amino acids
procedure
Prior art date
Application number
PE2001000970A
Other languages
English (en)
Inventor
Boris Chizh
Michael Heinrich Haurand
Claudia Katharina Putz
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20030617A1 publication Critical patent/PE20030617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE AL USO DE UNA AMINOACIDO DE FORMULA I DONDE R1 Y R2 SON ALQUILO C1-C10, ARILO, CICLOALQUILO C3-C10, HETEROARILO; R1 Y R2 SON UN CICLO (CH2)3-6 SATURADO O INSATURADO EN EL CUAL 0-2 ATOMOS DE C PUEDEN ESTAR SUSTITUIDOS POR S, O, NR4 DONDE R4 ES H, ALQUILO C1-C10; EN FORMA DE SUS RACEMATOS, ENANTIOMEROS, DIASTEREOMEROS O MEZCLAS. LOS AMINOACIDOS SE SELECCIONAN DE ACIDO 2-AMINO-3-METIL-HEPTANOICO, ACIDO 2-AMINO-3-METIL-OCTANOICO, ACIDO 2-AMINO-3-METIL-NONANOICO, ACIDO 2-AMINO-3-METIL-DECANOICO, ACIDO 2-AMINO-3-ETIL-HEXANOICO, ACIDO 2-AMINO-3-METIL-UNDECANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS AMINOACIDOS MENCIONADOS SON UTILES PARA EL TRATAMIENTO DE DOLORES NEUROPATICOS, CRONICOS, AGUDOS, MIGRANAS
PE2001000970A 2000-09-30 2001-09-28 Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen PE20030617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10048715A DE10048715A1 (de) 2000-09-30 2000-09-30 Verwendung von Aminosäure zur Behandlung von Schmerz

Publications (1)

Publication Number Publication Date
PE20030617A1 true PE20030617A1 (es) 2003-08-02

Family

ID=7658376

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000970A PE20030617A1 (es) 2000-09-30 2001-09-28 Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen

Country Status (13)

Country Link
US (1) US20030229145A1 (es)
EP (1) EP1326826A1 (es)
JP (1) JP2004511459A (es)
AR (1) AR034265A1 (es)
AU (1) AU2001289936A1 (es)
CA (1) CA2424089A1 (es)
DE (1) DE10048715A1 (es)
HU (1) HUP0302970A2 (es)
MX (1) MXPA03002740A (es)
NZ (1) NZ525417A (es)
PE (1) PE20030617A1 (es)
PL (1) PL361629A1 (es)
WO (1) WO2002030871A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
NZ539972A (en) 2002-12-13 2008-05-30 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CN1849153A (zh) 2003-09-12 2006-10-18 辉瑞大药厂 含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
EP1670750A1 (en) 2003-09-25 2006-06-21 Warner-Lambert Company LLC Prodrugs of amino acids with affinity for the alpha2delta- protein
US7354955B2 (en) 2004-01-07 2008-04-08 Abbott Laboratories (2S)-amino(phenyl)acetic acid and derivatives as α2δ voltage-gated calcium channel ligands
DE102004022572B4 (de) 2004-05-07 2012-02-16 Infineon Technologies Ag Integratorschaltung
CN101166524B (zh) 2005-04-28 2010-12-22 辉瑞有限公司 氨基酸衍生物
US8278355B2 (en) 2006-09-12 2012-10-02 Therexcell Pharma Inc. Isovaline for treatment of pain
PT2125021E (pt) 2006-12-22 2011-07-26 Recordati Ireland Ltd Terapia de combinação de distúrbios do tracto urinário inferior com 2 ligandos e nsaid
CN116655501A (zh) * 2023-05-23 2023-08-29 岳阳市康利医药化工有限公司 一种异氰基乙酸乙酯工艺流程中的优化合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854627C2 (de) * 1978-12-18 1980-07-03 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verfahren zur Herstellung von Aminocarbonsäurehydrochloriden bzw. Diaminocarbonsäure-di-hydrochloriden
CA1255037A (en) * 1984-06-29 1989-05-30 Barry L. Dickinson Protective helmet made from a polyarylate
EP0207580B1 (en) * 1985-04-05 1989-07-26 Texaco Development Corporation Process for the synthesis of n-acetyl amino acids from olefins, acetamide and syngas
DE68912822T2 (de) * 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
NL9101380A (nl) * 1991-08-13 1993-03-01 Dsm Nv Werkwijze voor de bereiding van een alfa-aminozuur, de overeenkomstige ester en amide.
DE4425068A1 (de) * 1994-07-15 1996-01-18 Degussa Verfahren zur Herstellung optisch aktiver L-Aminosäuren, neue optisch aktive L-Aminosäuren mit raumerfüllenden Seitengruppen und deren Verwendung
BR9708200A (pt) * 1996-03-14 1999-07-27 Warner Lambert Co Aminoácidos cíclicos substituídos como agentes farmacéuticos
GB9621789D0 (en) * 1996-10-18 1996-12-11 Lilly Industries Ltd Pharmaceutical compounds
JP3847934B2 (ja) * 1997-02-14 2006-11-22 株式会社カネカ γ−オキソ−ホモフェニルアラニン誘導体及びそれを還元してなるホモフェニルアラニン誘導体の製造方法
JP2001519806A (ja) * 1997-04-07 2001-10-23 アクシス ファーマシューティカルズ，インコーポレイティド セリンプロテアーゼ活性、特にトリプターゼ活性に関連する疾病を処理するための化合物及び組成物
AU1608399A (en) * 1997-11-26 1999-06-15 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
JP4205191B2 (ja) * 1997-12-26 2009-01-07 ダイセル化学工業株式会社 α−アミノニトリル誘導体及びα−アミノ酸の製造方法

Also Published As

Publication number Publication date
AU2001289936A1 (en) 2002-04-22
PL361629A1 (en) 2004-10-04
AR034265A1 (es) 2004-02-18
DE10048715A1 (de) 2004-05-19
CA2424089A1 (en) 2003-03-28
JP2004511459A (ja) 2004-04-15
WO2002030871A1 (de) 2002-04-18
US20030229145A1 (en) 2003-12-11
MXPA03002740A (es) 2003-07-28
NZ525417A (en) 2005-11-25
EP1326826A1 (de) 2003-07-16
HUP0302970A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
PE20030617A1 (es) Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
CO5570667A2 (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
AR056875A1 (es) Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
AR002241A1 (es) Derivado de 2,4-oxazolidinadiona, composicion farmaceutica que lo comprende y metodo de preparacion del mismo.
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
ES2113867T3 (es) Imino-derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
UY29702A1 (es) Inhibidores macrocíclicos del virus de hepatitis c
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
PE20250558A1 (es) Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno
AR070910A1 (es) Derivados de sulfonamida sustituida
AR041210A1 (es) Compuesto de piridazinona o piridona y uso farmaceutico del mismo
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
PE20050312A1 (es) Compuestos de peptidilo como inhibidores de catepsina s
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
AR041898A1 (es) Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales
AR041933A1 (es) Derivados de la 4-hidroximetil-1-aril-ciclohexilamina, metodos de preparacion de dichos compuestos y medicamentos que los contienen.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed